Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 7:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–5 of 5 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Autonomic Failure, Orthostatic Hypotension
Interventions
Atomoxetine, Acarbose, Pyridostigmine Bromide, Yohimbine, Midodrine HCl, placebo, Modafinil, Octreotide, water intake, Diphenhydramine Hydrochloride, Ranitidine HCL, Tranylcypromine, Ergotamine/ Caffeine, Celecoxib, Pseudoephedrine, Methylphenidate, Indomethacin, Ibuprofen, Oxymetazoline 0.05% nasal solution, Bovril, Acetazolamide, Rivastigmine tartrate, Carbidopa/levodopa, Inflatable abdominal binder, inflatable abdominal binder (sham)
Drug · Other · Dietary Supplement + 1 more
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 85 Years
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Barotrauma;Ear
Interventions
Hyperbaric Oxygen Therapy, Pseudoephedrine 60 MG, Placebo oral tablet
Procedure · Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 1 Interventional Accepts healthy volunteers

TransMEM Gas Exchange -- Project 1, Aim 2

NCT01925729
Conditions
Middle Ear Disease, Nasal Allergy
Interventions
ragweed, histamine, pseudoephedrine, Oxymetazoline
Biological · Drug
Lead sponsor
Cuneyt M. Alper
Other
Eligibility
18 Years to 50 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Acute Respiratory Infection, Bronchitis, Rhinosinusitis
Interventions
Mucinex D (600 mg guaifenesin and 60 mg pseudoephedrine HCl extended-release bi-layer tablets)
Drug
Lead sponsor
Adams Respiratory Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
28
States / cities
Birmingham, Alabama • Carmichael, California • Torrance, California + 24 more
Conditions
Acute Cholecystitis, Chronic Cholecystitis
Interventions
TIVA - Hypotension, TIVA - Hypertension, TIVA - Bradycardia, TIVA - Tachycardia, INH - Hypotension, INH - Hypertension, INH - Bradycardia, INH - Tachycardia
Procedure
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Antonio, Texas